|Aliases: CUDC101, 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide|
|Catalog No: 14060||Format: 25 mg||$450||Buy|
|Catalog No: 14061||Format: 5 mg||$125||Buy|
|Application: Histone Acetylation (HAT & HDAC)|
MW = 434.5
MP = 188-190°C
>99% (HPLC); NMR (Conforms)
A novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2 (IC50 = 4.4 nM, 2.4 nM and 15.7 nM respectively) (ref 1). It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors (ref 1,2).
White to off-white powder. May be dissolved in DMSO (25 mg/ml).
Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month.
1. CJ Lai et al. Cancer Res. 2010, 70:3647
2. X Cai et al. J. Med. Chem. 2010, 53:2000